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Early clinical outcome and toxicity profile from a
retrospective analysis of 138 patients
Po-Ming Wang1, Wei-Chung Hsu1,2, Na-Na Chung1, Feng-Ling Chang1, Antonella Fogliata3* and Luca Cozzi3Abstract
Background: To report early outcome and toxicity for inoperable patients with hepatocellular carcinoma (HCC)
treated with volumetric modulated arc therapy (VMAT).
Methods: One hundred and thirty eight patients were retrospectively analysed. Dose prescription ranged from 45
to 66Gy with conventional fractionation regime. Based on AJCC staging, 88.4% presented stage III or IV. Two-thirds
(69.6%) were Child-Pugh stage A, the remaining were stage B. According to Barcelona Clinic Liver Cancer staging,
72.5% of patients were classified as stage C.
Results: Median age was 66 years, median tumor volume was 516cm3 (28 to 3620cm3). The most patients (83%)
were treated with 60Gy. Median follow-up time was 9 months. One-year overall survival rate was 45% (100% for
AJCC stage I, 83% for stage II, 45% for stage III and 28% for stage IV), median survival was 10.3 months (95% C.I.
7.2-13.3). Local control was achieved in 94% (of 109 assessable patients), stable disease in 29%, partial response in
53%, complete response in 11%, and progression in 6%. Radiation-induced liver disease was observed in 34 patients
(25%). Gastrointestinal grade 3 toxicity was modest with a total of 17 (12.3%) cases for all endpoints.
Conclusions: Clinical results could suggest to introduce VMAT as an appropriate technique for the patients with
HCC.
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Hepatocellular carcinoma (HCC) is the third cause of
cancer death and one of the most challenging onco-
logical problems [1]. Surgery, although providing sur-
vival rates up to 70% at 5 years [2], is viable in a small
fraction of patients (less than 1/3) because of advanced
stage at diagnosis. Patients also can be treated with
transcatheter arterial chemoembolization (TACE), radio-
frequency ablation (RFA), percutaneous ethanol injection
(PEI), chemotherapy and targeted agents [3-6] with com-
plex decision trees and limited impact on outcome.
Radiotherapy was offered to HCC patients but it was
limited by severe radiation induced liver disease (RILD)* Correspondence: antonella.fogliata-cozzi@eoc.ch
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reproduction in any medium, provided the orwhen excessive fractions of the liver were involved in the
radiation field [7] and the important relationship be-
tween the volume of irradiated normal liver and the tox-
icity profile [8-10]. After the introduction of intensity
modulated radiotherapy (IMRT), a new hope emerged
for radiotherapy in HCC patients [11,12]. Recently,
IMRT evolved into the so-called volumetric modulated
arc therapy (VMAT). VMAT was pioneered in its Rapi-
dArc mode by Otto [13] and technical details can be
found elsewhere [14]. In liver, clinical application of
RapidArc was primarily limited to metastatic indications
[15]. A planning study from Kuo et al. demonstrated
that RapidArc also play a role in HCC [16]. Stereotactic
body radiation therapy (SBRT) approaches have been
hypothesized for smaller target and in cases requiringtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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volume) [17].
Here, we report about the clinical application of Rapi-
dArc to HCC in a cohort of patients, demonstrating the
feasibility and the early clinical outcome on a large pa-
tient population. Conventional fractionation and total
dose were adopted because of the stage and the large
median tumor size.Methods
Patients
Between February 2009 and December 2010, 138 con-
secutive HCC patients presented Barcelona Clinic Liver
Cancer (BCLC) stage A to C and were eligible for cura-
tive or palliative radiotherapy (in eventual association to
other therapeutic modalities) at the home institute.
Figure 1 represents the institutional guidelines for HCC
treatment. In brief, BCLC stages A to C, Child-Pugh
stages A-B with single lesions larger than 5cm or multi-
nodular lesions larger than 3cm were eligible for radio-
therapy. All patients were inoperable or not eligible for
TACE treatments and received radiotherapy as primary
treatment. Portal vein thrombosis was present in about
50% of the cases. Relative contraindication to inclusion
were: total bilirubin levels greater than 3 to 5 mg/dL;
white blood count (WBC) less than 2500–1500 U/?L;
Glutamic pyruvic transaminase (GPT) in the range 100–HCC Treatment Guideline
HCC
Stage A-C
PST 0-2, Child-Pugh A-B
Early stage A






























Figure 1 Schematic representation of the institutional guidelines for300 U/L. Absolute exclusion criteria included total bili-
rubin >5 mg/dL, WBC<1500 U/?L and GPT>300 U/L.
Radiation treatment
Dose prescription was of 45, 60 or 66Gy in 1.8 or 2.0Gy/
fraction depending upon stage, location of target and its
size and general conditions of patient. Plans were
designed for single course treatments of for sequential
boosting on reduced volumes technique. In case of
boost, three schemed were adopted: i) 60Gy total dose
in two courses: 40Gy+20Gy; ii) 45Gy in two courses:
36Gy+9Gy; iii) 45Gy in three courses: 27Gy+9Gy+9Gy.
Patients receiving a single course were treated at 66Gy.
For those patients with tumor near gastrointestine tract,
45Gy in two or three courses were designed by the
shrinkage of tumor and prevention for gastrointestine.
The dosage and boost scheme were predetermined by
the decisions of the physician. If the dose constraints
couldn’t be satisfied, boost schemes were applied to de-
crease normal tissue complications. As an example, for
existing duonenal ulcer, gastric ulcer, reflux esophagitis
patients, 36+9Gy boost was applied to minimize
radiation-induced ulcer. When OARs included stomach,
duodenum and colon, the 40+20Gy scheme was applied.
The gross tumor volume (GTV) was defined as the pri-
mary tumor plus abnormal portal areas revealed on CT
images (IV contrast was used for all patients except for
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the treatment management of HCC patients.
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ning CT for more precise target delineation). The clin-
ical target volume (CTV) was defined as the GTV plus a
1cm margin. The planning target volume (PTV) was
defined as the CTV plus 0.5cm axial and 1–2.5cm
cranial-caudal individualized margins. Boost volumes
were definied with repeated CT scans if needed.
Plans were normalized to 95% of the planning target
volume (PTV) (D95%=100%). For all patients, in addition
to the target volume PTV, the entire liver, the normal
liver (liver-PTV), the kidneys, the stomach, the spinal
cord and the lungs were outlined and considered during
optimization. The following explicit planning objectives
were defined: for the total liver V30Gy<60%, for the nor-
mal liver (liver-PTV); V15Gy<30%, for the PTV a mini-
mum dose greater than 90%; and a maximum dose
lower than 115-140%.
All patients were treated with VMAT in the form of
RapidArc [13,14] with 10 MV photons. Individualized
optimization was performed using single or multiple, co-
planar or non-coplanar, mono-isocentric arcs.
All patients were treated in supine position with arms
placed overhead and were immobilized with an indivi-
dualized vacuum cushion on the patient tray. A real-time
infrared tracking device (ExacTrac; BrainLab AG,
Heimstetten, Germany) was used for patient immobilization
and reposition during the CT scan and treatment.
Evaluation
Dosimetric and technical parameters of delivery were
scored including some delivery parameters as well as
standard analysis of dose volume histograms (DVH).
Guidelines of International Commission on Radiation
Units and Measurements (ICRU) 83 report were applied
as far as possible [18]. Clinical evaluation was per-
formed, with reference to baseline conditions deter-
mined before start of treatment, during treatment and at
1, 2, 3,6 months after treatment completion: basic treat-
ment outcome was measured in terms of in-field local
control (visits included laboratory assessment and CT
and MRI imaging (at 2 to 3 month intervals for at least
2 years and at 6 month intervals thereafter)) and patient
overall survival and it was scored continuously with a
total follow-up of maximum 28 months. Tumor re-
sponse was assessed using Response Evaluation Criteria
in Solid Tumors (RECISTs) criteria. Local in field recur-
rence was defined by new enhancement or progressive
disease with CT or MR imaging during follow-up. Actu-
arial survival and local control rates were determined by
standard Kaplan-Meier analysis and several factors were
tested to ascertain significant differences between sub-
groups of patients. Univariate and multivariate analysis
were similarly performed to identify variables relevant
for survival prediction. RILD (in absence of progressiveliver disease), was defined by Lawrence’s criterion [7].
Conventional definition of classical RILD [9] manifested
within 4 months after the completion of irradiation as
either anicteric elevation of alkaline phosphatase level to
at least two-fold of the upper normal level and nonma-
lignant ascites, is not common in Asia. Instead, non-
classic RILD is dominant and GPT elevation indicates
hepatocyte damage. Bujold [3] defined non-classical
RILD as a 5-time elevation in liver transaminases. The
significant liver dysfunction is often difficult to differen-
tiate treatment-induced hepatic toxicity from progressive
tumor or dysfunction exist prior to treatment such as
cirrhosis or previous treatment. Thus, we defined RILD
as elevated transaminase of at least two-fold the upper
limit of normal or pretreatment levels based on the Na-
tional Cancer Institute Common Toxicity Criteria for Ad-
verse Events (CTCAE) version 4.03. Gastrointestinal (GI)
toxicity was also scored according to CTCAE 4.03. End-
points included esophagitis, gastritis, gastric hemorrhage
or ulceration, duodenal hemorrhage or ulceration and
ascites.Results
Patients
Of the 138 patients treated with RapidArc included in
the analysis, Twenty-nine patients were not assessed in
terms of treatment response because either dead (21) or
lost to follow-up (8). Table 1 reports the characteristics
of the cohort of patients included in the study. Concern-
ing stage, the vast majority of the cases presented
advanced local diseases: BCLC stage C in 72.5% of the
population, AJCC stage III and IV in 88.4% of the cases.
About half of the cases were with portal vein throm-
bosis; 86.2% had history of hepatitis. For all patients, me-
dian tumor volume was 516 cm3 (ranging up to
3621cm3) corresponding to 33% of the median total liver
volume.Treatment
Almost (88.4%) patients received either 60 or 66Gy and
about 61% were treated with one or more volume reduc-
tions (cone-down). About 88% of the patients were trea-
ted with 2Gy/fraction, 12% with 1.8Gy/fraction. Nearly
99% of the patients were treated with multiple partial
arcs and 93% were optimized with a non-coplanar
setting.
Table 2 shows results from the dose-volume histogram
(DVH) analysis for target volumes and organs at risk.
The planning objective on V30Gy for total liver and on
V15Gy for normal liver (liver-PTV) were on average
respected together with a substantially full coverage of
the PTV (V95% and D95% showed a minimum value of
96% and 96.8%).
Table 1 Characteristics of the cohort of patients
Characteristics Items N (%)
Sex Female 26 (18.4%)
Male 112 (79.4%)
Age Mean 64
Median (range) 66 (30–87)
St.dev 11
Portal Vein Thrombosis No 64 (46.4%)
Yes 74 (53.6%)
Tumor location Right lobe 57 (41.3%)
Left lobe 10 (7.2%)
Bilateral lobe 71 (51.4%)
Stage T T1 8 (5.8%)
T2 10 (7.2%)
T3 120 (86.9%)
Stage N N0 114 (82.60%)
N1 24 (17.4%)
Stage M M0 116 (84.1%)
M1 22 (15.9%)




Okuda Stage I 31 (22.4%)
II 107 (77.6%)
BCLC Stage A 9 (6.5%)
B 29 (21.0%)
C 100 (72.5%)
Child-Pugh Stage A 96 (69.6%)
B 42 (30.4%)
Hepatitis No 19 (13.8%)
B 71 (51.4%)
C 43 (31.2%)
B and C 5 (3.6%)
Initial Alpha-fetoprotein (?g/L) Median (range) 11481 (2.4 – >58300)
Initial white blood count (kU/?L) Median (range) 5.9 (2.7 – 15.6)
Initial haemoglobin level (g/dL) Median (range) 12.8 (7.0 – 19.0)
Initial GPT level (U/L) Median (range) 50.0 (8.8 – 396.0)
Initial total bilirubin level (mg/dL) Median (range) 0.9 (0.3 – 8.5)
Initial tumor volume (cm3) Median (range) 516 (28 – 3621)
Total liver volume (cm3) Median (range) 1587 (548 – 5489)
Dose prescription 45Gy 16 (11.6%)
60Gy 114 (82.6%)
66Gy 8 (5.8%)
Values refer to number of patients, % to the total number of 138 patients.
AJCC: American joint Committee on Cancer, BCLC: Barcelona Clinic Liver Cancer. HCC: hepatocellular carcinoma. TACE: transarterial chemo-embolisation.
RFA: radio-frequency ablation. GPT: Glutamic Pyruvic Transaminase.
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Figure 2 shows survival estimates after Kaplan-Meier
analysis for the whole cohort of patients (n=138) and
factorized according to some of the variables leading
to significant differences. Mean survival time resulted
13.5 months (95% C.I.: 11.6–15.3 months), median
resulted 10.3 months (95% C.I.: 7.2-13.3 months).Overall survival (OS) at 12 months resulted 45±5%, at
24 months 28±5%. One-year OS based on AJCC stage
was: stage I: 100%; stage II: 83%; stage III: 45%; stage IV:
28%. The same OS classified by BCLC is: stage A 85.1%
(4 patients alive), B 74.1% (19 patients alive), C 32.5%
(24 patients alive). Table 3 summarizes the mean OS
time factorized according to some of the main
Table 2 Summary of the DVH analysis for the target
volume and for the organs at risk for the entire cohort of
patients
Organ Parameter
PTV D95% [%] 100.8±6.2 [96.0;108.0]
V95% [%] 99.0±1.8 [96.8;100.0]
Mean [%] 110.1±2.6 [101.7;120.6]
Left Kidney Mean [Gy] 5.22±4.5 [0.2;21.2]
D1cm3 [Gy] 12.3±8.3 [0.4;34.9]
Right Kidney Mean [Gy] 8.2±7.2 [0.1;26.9]
D1cm3 [Gy] 28.1±18.7 [0.3;62.6]
Spinal Cord D1cm3 [Gy] 21.8±9.0 [1.1;47.6]
Stomach Mean [Gy] 14.6±5.7 [3.0;36.6]
D1cm3 [Gy] 31.7±10.9 [8.5;58.2]
Liver-PTV (Normal liver) Mean [Gy] 19.4±6.3 [1.9;33.4]
V15Gy [%] 24.4±11.6 [0.6;56.4]
Total Liver Mean [Gy] 32.1±11.5 [2.3;55.4]
V30Gy [%] 46.4±19.7 [1.4;85.4]
Data are reported as average values plus or minus standard deviation;
in square brakets the range.
Dx%: dose received by at least x% of the volume.
Vx%: volume receiving at least x% of the dose.
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that the following variables are significant with respect
to survival (in parenthesis the significance): sex (p=0.05),
age (p=0.006), total dose (p=0.01), tumor volume
(p<0.001), localization (p=0.03), portal vein thrombosis
(p<0.001), AJCC stage (p<0.001), BCLC stage (p<0.001),
normal liver volume (p<0.001), T stage (p<0.001), base-
line alpha fetoprotein (AFP) level at before therapy
(p=0.03), volume of total liver receiving more than 30Gy
(p=0.001). In a multivariate analysis, the following vari-
ables resulted statistically significant: total liver volume
(p=0.001), tumor volume (p=0.002), total liver volume
irradiated more than 30Gy (p=0.02), portal vein throm-
bosis (p=0.001), T stage (p=0.001), AJCC stage (p=001),
BCLC stage (p<0.001) and baseline alpha fetoprotein
level (p=0.02). Survival did not resulted significantly dif-
ferent (p=0.11) if factorized according to Okuda stage I
and II.
Response and toxicity
The mean time to local response was 8.8 months (95%
C.I.: 7.9–9.7 months). The responses were: progressive
disease (PD): 6.4% (7 of 109 assessed patients) with a
mean time to progression detection of 3.1±2.3 months
(range 1.1 to 7.2 months); stable disease (SD): 29.4% (32
patients) with mean time to detection of 4.0±1.3 months
(range: 1.4-6.8 months); partial response (PR): 53.2% (58
patients) mean time to response of 4.6±1.3 months
(range: 1.2-8.9 months); complete response (CR): 11.0%
(12 patients), mean time to complete response of 4.9±1.7months (range: 3.0-9.8 months). Twenty-nine patients
were not assessable as described above. Hundred and two
patients responded with progression-free (SD+PR+CR),
93.5% of the assessed group or 73.9% of the entire cohort
of 138 patients.
AFP level was monitored and its reduction from base-
line (before treatment) to the end of radiotherapy
resulted highly significant for the entire cohort of
patients (20% reduction, p<0.01). Total reduction and
significance remained high at 1, 3 and 6 months (reduc-
tion of 27%, 27% and 29%; p=0.01, p<0.01 and p=0.03).
Different trends were observed for the two risk groups
(baseline AFP between normal level to 400ng/L versus
greater than 400ng/L). For the first risk group, AFP
increased during treatment and follow-up: +22% at end
of treatment, +173% at 1 month after end of treatment
and +228% at 3 months with high significance of differ-
ences. The patients belonging to the highest risk group,
showed, on the contrary, a remarkable reduction of AFP:
20% at the end of treatment, 29% at one and 3 months
(p<0.01, p<0.01, p=0.03). The relative majority of PR or
CR (29/70) were observed in the AFP highest risk group.
No impact was observed on total bilirubin levels be-
tween baseline and end of therapy. A significant drop in
WBC was observed between baseline and end of therapy
(p=0.01), partially recovered but still significant at 3 and
6 months. For hemoglobin levels, the trend is similar
with WBC.
Concerning treatment toxicity, non-conventional RILD
was observed in 34 cases (25% of 138 patients), but the
most cases (24/34) were grade 1 or 2 toxicities (Table 4).
Four patients with severe RILD (grade 3 or 4) were
observed in the AFP first risk group (AFP from 8.04 to
400ng/mL) and 3 in each of the normal level or high risk
groups. GI toxicity is summarized in Table 4 and
resulted mild. For each endpoint grade 3 was observed
in 1-2% of cases while grade 1–2 ranged from 2%
(esophagitis) to 23% (ascites).Discussion
The current study demonstrated the possibility to treat
HCC patients with RapidArc safely and effectively within
a conventional fractionation scheme and total dose ran-
ging from 45 to 66Gy. Patients treated were mostly in
advanced stages (>90% in BCLC stages B and C) with
frequent presence of portal vein thrombosis. Early
results in terms of overall survival and local control
demonstrated a high level of local control (94% of the
assessable patients) and the overall survival at 12 months
resulted 45% (significantly higher for earlier stages). A
significant clinical effect at biochemical level was
observed in the decline of the AFP levels at the end of





Figure 2 Survival plots for the whole cohort of patients and factorized according to some significant variables.
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patients with poor baseline.
The application of non-coplanar rotational technique
with intensity modulation is a unique characteristic in
this study. RapidArc allowed to spare normal liver tissue
and led to be an acceptable treatment option for those
patients ineligible for surgery or other ablative treat-
ments. Because of the advanced stage, it was not pos-
sible to add also hypo-fractionated regimen for these
HCC patients. Therefore, although this modality hasbetter or similar effect in tumor response as the stand-
ard treatment, any comparison against other published
studies has to account for the trade-off between the in-
novative technique and the limits of conventional frac-
tionation. Given the short follow-up, results might be
time-biased (local control might be overestimated or
toxicity under-estimated) in present study. However, it is
important to position the new treatment technique in
the frame of consolidated experience of other groups.
Hsu [19] reported about bi-fractionated treatments with
Table 3 Summary of the mean probability of survival factorized according to significant variables
Factor Probability of survival (months) [95% C.I.] P value
Sex Male: 13.1 [11.1 – 15.1] 0.05
Female: 15.2 [11.4 – 19.0]
Portal vein thrombosis No: 17.7 [14.9 – 20.5] <0.001
Yes: 10.1 [7.9 - 12.3]
BCLC stage A: 25.7 [20. – 30.9] <0.001
B: 20.1 [16.3 – 23.9]
C: 13.5 [11.7 – 15.4]
Child-Pugh A: 14.8 [12.6 – 17.1] 0.02
B: 9.9 [7.3 – 12.6]
Hepatitis No: 16.6 [12.1 – 21.1] 0.05
B: 10.9 [8.6 – 13.3]
C: 16.3 [12.9 – 19.7]
B&C: 10.5 [4.1 – 16.8]
Baseline AFP Baseline: 17.2 [12.8 – 21.6] 0.03
Low risk:14.6 [11.5 – 17.7]
High risk:9.3 [7.7 – 10.9]
Tumour localisation Right lobe: 14.6 [11.5 – 17.6] 0.03
Left lobe: 20.0 [15.7 – 24.3]
Bilateral: 11.8 [9.4 – 14.2]
Total dose 45 Gy: 8.6 [5.1 – 12.1] 0.01
60 Gy: 13.5 [11.4 – 15.5]
66 Gy: 25.9 [21.1 – 30.7]
Volume of normal liver Receiving >15Gy <30%: 21.0 [17.6 – 24.4] 0.001
>30%: 18.6 [16.9 – 20.4]
In brakets the 95% confidence interval level.
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survival was 60%. Krishnan [20] reviewed studies of
radiotherapy in liver including typically TACE, 1 year
survival ranged from 42% to 94% for doses ranging from
30 to 66Gy. Seong [21] demonstrated 158 patients trea-
ted with conventional fractionation scheme and in com-
bination with TACE. One-year and 2-year OS was 40%
and 20% with a median survival of 10 months,Table 4 Summary of toxicity profiles based on CTCAE
criteria
Gr 1 Gr 2 Gr 3 Gr 4
RILD 12 (9%) 12 (9%) 8 (6%) 2 (1%)
Esophagitis 1 (1%) 2 (1%) 2 (1%) -
Gastric Hemorrhage 0 (0%) 8 (6%) 3 (2%) -
Gastric Ulcer 1 (1%) 17 (12%) 3 (2%) -
Gastritis 4 (3%) 11 (8%) 1 (1%) -
Duodenum Hemorrhage 0 (0%) 4 (3%) 3 (2%) -
Duodenum Ulcer 3 (2%) 13 (9%) 3 (2%) -
Ascites 11 (8%) 21 (15%) 2 (1%) -respectively. Seong also found that total dose was the
only significant factor influencing survival and the mean
prescribed dose was 48Gy. Data from this study demon-
strated a similar effect with a huge difference between
the three-dose levels administered (although masked by
several other prognostic factors in the dose level assign-
ment). Seong reported comparable results in terms of
local control compared to this study. Skinner [22]
reported a small cohort of 29 patients demonstrating
once more the relevance of total dose to improve out-
come. Patients treated with lower total doses (biological
effective dose <75Gy) resulted in 1-year OS of only 18%
against 69% for the complementary group. Given these
perspective and the results of the present study, it is
conceivable to escalate the dose prescribed with Rapi-
dArc also for advanced stage patients with HCC. Yoon
[23] analyzed clinical outcome for 412 patients treated
with TACE and 3D conformal radiotherapy for HCC
with portal vein thrombosis. For these patients, median
survival was 10.6 months with 42.5% survival rate at one
year consistent to the data reported in the present study
(35% survival for PVT positive patients).
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between outcome and AFP levels before treatment.
Patients within the highest risk group of AFP had the
most significant reduction of the same during follow-up.
Although no definitive answer can be provided here, one
possible interpretation, might be related to the fact that
non-significant AFP elevation will occur when either
hepatitis reactivation or change of cirrhosis status will
occur after radiotherapy. Thus, for those patients with
lower AFP levels (first risk group), the AFP might be in-
creasing because of the effects of inflammation/cirrhosis
are higher than therapeutic effect in the early follow-up
period. On the contrary, for those patients with higher
AFP levels (high risk group), even assuming a similar
proportion of tumor cell killing as within the first group,
the absolute AFP values will decrease more.
Finally, an advantage of RapidArc is its effective ‘rapid’
delivery time. This might overcome most of the problem
of respiratory motion in abdominal tumours, especially in
HCC patients. In particular, conventional respiratory gating
may not be feasible for HCC patients (breath hold or deep
inspiration are impractical for the patients with huge HCC
and massive ascites). While for most advanced stages, re-
spiratory motion could be automatically accounted for by
the extension of margins, for earlier stages, the usage of
time resolved CT scan (4DCT) for planning might help to
understand the liver excursion and to better individualise
the margins to PTV. This is particularly important in those
cases where dose escalation might be envisaged.
Conclusion
The cohort of 138 patients suffering of HCC was treated
with VMAT. Early results in terms of OS and local control
were adequate and consistent with similar reports demon-
strating the appropriateness of the RapidArc technique for
advanced HCC patients. Toxicity profile was mild. Dose
escalation might be considered to improve survival, either
increasing the total dose or, for earlier stages, considering
the SBRT solution. Longer follow-up will allow to consoli-
date these early observations.
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